Abstract
immunization. 23
As opposed to active immunization platforms (requiring the use of whole or portions of pathogens as 24 vaccines), the rapidly developing passive immunization involves administration of either pathogen-25 specific or broadly acting antibodies against a kind or class of pathogens as a prophylactic treatment to 26 corresponding acute infection. Several antibodies with broadly acting capacities have been discovered 27 that may serve as means to suppress influenza viral infection and allow the process of natural immunity 28 to engage opsonized pathogens whilst boosting immune system by antibody-dependent mechanisms 29 that bridge the innate and adaptive arms. By that, passive immunotherapeutics approach assumes a 30 robust tool that could aid control of influenza viruses. In this review, we comment on some 31 improvements in influenza management and promising vaccine development platforms, with emphasis 32 Introduction viruses infect a common host and generate novel virus subtypes or strains (11, 12) . Thus, antigenic 68 shifts (principally underlying influenza A virus pandemics) and antigenic drifts (underlying vaccine 69 mismatches against seasonal influenza A and B viruses) and wide host-range (for influenza A viruses) 70 are responsible for the recurring cases of influenza all year round (13, 14) . Furthermore, antigenic drifts 71 and shifts are particularly reasons for which there is an immediate need for highly efficacious 72 intervention. We review here vital influenza management strategies, novel vaccine and antiviral 73 development approaches with deliberation on those with prospects. 74
Current influenza vaccines 75
Three types of vaccines against influenza are currently used worldwide including inactivated influenza 76 vaccine (IIV), live -attenuated influenza vaccine (LAIV) and influenza virus subunit vaccine: each of 77 which has its own advantages and drawbacks. IIV is formulated with replication-incompetent virus, due 78 to whole pathogen inactivation usually achieved by formaldehyde treatment or split virion vaccines 79 generated by disruption of the viral membrane (15). Intramuscular administration of the IIV has been 80 shown to induce both local and systemic immunity (16). However, to maintain the antibody titers, 81 booster vaccinations are required. Additional considerations on the vaccine efficacy were raised 82 following metadata analysis suggesting only 40% of children being protected against influenza, with 83 the percentages going a bit higher up to 65% for the adults (17, 18) . LAIV comprise of re-assortant 84 viruses generated from cold-adapted donor viruses (that contribute their internal genes) and identified 85 virulent circulating strains of viruses [that contribute their HA and neuraminidase (NA)] as 86 recommended by the WHO. Cold-adapted donor viruses are raised by several passages in embryonated 87 chicken eggs with gradual reduction in temperature during every round of passage. By this process, re-88 assortants viruses that comprise of the LAIV can grow at 32-33°C, the temperature range of cells lining 89 the mucosal surfaces of the nasopharynx, when administered intranasally (19) . Replication of LAIV 90 viruses in the nasopharynx elicit immune response that epitomizes a natural influenza infection. For 91 this reason, LAIV has shown some superiority over the IIV in terms of the induction of mucosal 92 immunity via secreted immunoglobulin A (19).Use of the LAIV has proven to be safe in children (15 93 to 71 months) and immunocompromised persons (HIV-infected, chronic bronchitis and cystic fibrosis) 94 (20-22). The most spelt-out advantage is the "non-invasive" capacity of the attenuated viruses and this 95 had made it suitable to use for all categories of vaccinees, although LAIVs are not recommended for 96 people with underlying chronic medical conditions (23). For the further induction of a stronger 97 immunity, adjuvants such as MF59 can be added to both inactivated virus and LAIV vaccines. 98 Noteworthy, adjuvant reagents including squalene oil, Tween 80, Span 85 and citrate buffer on their 99 own were shown not to have any enhancing vaccine effect, the combination of all has resulted in 100 induction of immune cell migration to the site of vaccination increasing vaccine efficacy. However, a 101 typical setback to the use of the LAIV is the possibility of the attenuated virus undergoing some genetic 102 modifications and consequently reverting to virulence, a case which has not been reported for the LAIV 103 there are still no clearly underpinned core reasons (34). Therefore, together with improving vaccines, 138 there is need to understand the medical, socio-economic and vaccination challenges. 139
Novel influenza vaccine platforms

140
Rapid influenza virus evolution and yearly vaccine reformulations make the stockpiling of vaccines for 141 future use a complicated issue. This subsequently delays preparation against any unforeseen epidemics. 142 Therefore, lots of researches are now focusing on the development of novel broadly protective vaccine 143 platforms, with hopes of enhancing both immunogen delivery and consequent immune response to 144 select antigens. Some of these platforms include virus-like particle vaccines (VLP), synthetic virus 145 vaccines, epitope vaccines, antigen-presenting cell inducible vaccines, COBRA vaccines, nanoparticle-146 based vaccines and viral-vectored vaccines (Table1). 147
Virus -like particle (VLP) vaccines 148
Virus-like particles are non-infectious multimers of viral capsid proteins that have the propensity to 149 self-assemble (35). VLPs are designed to maintain their native viral structure, but without their complete 150 set of genetic materials. A typical influenza VLP has the HA, NA and the matrix protein 1 (M1). 151
Typically, plasmid constructs of the HA, NA and M1 are used to transfect cells: resulting in formation 152 of the capsid displaying surface proteins HA and NA (36). VLPs have been proposed to be efficient 153 vaccines against a range of viruses including human papilloma virus (HPV) and hepatitis B virus (HBV) 154 or hepatitis E virus (HEV) as discussed by Zhao et al. (37) . Although these examples have completely 155 different "biologies" when compared with the influenza virus, rapid advances and need for a new 156 vaccine platform are generating some promising data for influenza VLPs. For instance, to overcome 157 challenges raised by rapid influenza evolution Gao et shown to induce both cellular and humoral immunity in mice and it is envisaged as able to overcome 210 high virus mutation rates (56). The epitope-based vaccination therefore affords the direct involvement 211 of B and T lymphocytes that are both required for effectual control of viruses during an infection. 212
Antigen-presenting cell (APC) inducible vaccines 213
Recently, more focus is drawn to increasing the abilities of antigen-presenting cells (APCs) with possible spillover events from avian into humans (85). It is imperative to note that there are still 276 NA inhibitor-sensitive influenza A viruses in circulation, and this drug class can be extremely helpful 277 in the management of an outbreak or even, a pandemic in the absence of highly efficacious vaccines. 278
Novel influenza management therapies 279
Next-generation antivirals against influenza 280
High frequency of infections with influenza virus requires identification of a novel compounds that 281 have the potential to alleviate the symptoms and reduce viral shedding. New research focuses are 282 developing not only virus targeting antivirals but also the ones that target the host organism (Table 2) . 283 H5N1 and group 2 such as H7N9 and also drug-resistant strains of these viruses and has been exploited 321 for the treatment against other viruses e.g. Ebola virus (107). Efficacy of T-705 for treatment of 322 influenza has thus warranted its advancement through phase III and II trials in Japan and US 323
respectively (108). 324
Baloxavir marboxil is another antiviral which was first developed in Japan and was shown to act as a 325 selective cap-dependent endonuclease inhibitor of influenza viruses' (both A and B) polymerase subunit 326 PA. The drug had exhibited preferable safety, tolerability and pharmacokinetic properties in a phase I 327 trial (109). The overall optimal performance against uncomplicated influenza among adults and 328 adolescents, was shown during phase II and III trials that involved Japanese and Americans respectively 329 (110). The drug has currently been approved and marketed in the US as Xofluxa, for the treatment of 330 acute uncomplicated influenza among ≥ 12 years (111). 331
Arbidol (Umifenovir) is another influenza-limiting drug that had previously been licensed for use in 332 both China and Russia, for almost several decades (112, 113). It was originally developed in Russia and 333 was found to potently inhibit influenza virus fusion with susceptible cell membranes, followed by 334 interferon induction (112). Like other broad-spectrum antivirals discussed earlier, besides influenza 335 viruses, Arbidol has been shown to efficiently suppress other viral infections caused by 336 paramyxoviruses and picornaviruses, bunya viruses, rhabdoviruses, reoviruses, togaviruses, 337
hepaciviruses, Ebola virus, arenaviruses, herpesviruses and the flaviviruses (Zika virus, West Nile virus 338
and Tick-borne encephalitis virus) (114-117). Currently, phase III trial of the Arbidol in ongoing in 339
China and the drug is also due phase IV trial (with an unknown status) in Russia. 340
Ingavirin, a drug developed in Russia, adds on the current list of influenza-limiting antivirals due to its 341 direct interference with the transportation of newly synthesized viral NP (118-120). As of 2017, 342
Ingavirin has been approved for the treatment of influenza and other viral causes of acute respiratory 343 illness, in Russia, following the completion of phase IV trial. 344 Table 2 and that the binding of their heavy-chain complementarity determining region (HCDR) to the HA stem 380 critically depends on two conserved residues: Phe54 and Tyr98 in HCDR3 (128). Discovery of mABs 381 that can cross-neutralize multiple viral subtypes could lead to novel passive immunotherapy treatments 382 for human infections and could also have the potential to abrogate spillover infection events from 383 zoonotic species. Several examples with the highest potential for use in management of influenza, are 384 listed in Table 3 . 385 Table 3 
394
Experiments by Lu and colleagues demonstrated that the Fragment antigen-binding, F(ab') 2 region of 395 an equine anti-H5N1 antibody could protect mice against a lethal challenge of influenza H5N1 (129) . 396
Such an example shows that use of passive immunotherapy during influenza outbreaks could 397 complement the use of available antivirals that would increase the survival in both humans and other 398
animals. 399
Most antibodies tend to be elicited against the more antigenically variable head domain of the major 400 surface glycoprotein HA. On the other hand, the less variable stalk domain is characterized as sub- have been shown to confer this kind of protection amongst either vaccinees who were previously 447 immunized against a specific influenza virus strain or persons who had acquired immunity to an 448 influenza strain via natural infection with a specific influenza virus strain (142). ADCL is another 449 mechanism that could augment the killing of influenza viruses as observed by Terajima et al, realizing 450 that mostly neutralizing human monoclonal antibodies (either recognizing the globular head or stalk of 451 HA) exerted this kind of effect, contrary to previously associated stalk-specific antibodies only (145) . 452
Above all, we emphasize the therapeutic capacity of novel monoclonal antibodies in combating 453 influenza infection, in coherence with the sentiments for the other publications. In addition to the use 454 of effective antivirals, passive immunotherapy against both influenza A and B viruses might be the 455 way-forward for influenza virus management amongst all class (be it high-or low-risk) of patients. We 456 envisage that the involvement of passive immunization will culminate in an accelerated relief through 457 any of the mechanisms previously described, and this provides allowable time for the full activation of 458 the adaptive immune system via the conventional antigen-presenting mechanisms. Additionally, 459
infected persons who were passively immunized could develop a natural immunity to the specific 460 viruses and this immunity could be long-lasting giving protection to other antigenically-matched strains. 461 (146). Also, the association of passive immunization with rapid relief increases the chances of abating 462 the evolution of escape mutants suggested to arise due to vaccination and its consequent herd immunity 463 (147). 464
Conclusions 465
Overall, synthetic approaches that have the potential to facilitate a broad-scale vaccine virus production, 466 may equally be potential in a broad-scale generation of monoclonal antibodies for the purpose of 467 immunotherapeutic intervention among people who are confirmed positive for influenza by standard 468 laboratory techniques, or even against any unlikely unforeseen future pandemics, by use as a 469
prophylaxis. We project our views on the prospects of passive immunization as an effective influenza 470 management tool. 471 
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